Samsung and Biogen Idec team up to make biosimilars in S Korea
This article was originally published in Scrip
Executive Summary
Samsung is continuing to make inroads into the biosimilars segment with a new $300 million joint venture with Biogen Idec. Although Biogen will only invest $45 million for a 15% stake, it has secured a clause which stops the joint venture making biosimilars of Biogen products.